Position in PCVX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$22,594,084
-$2,316,627 QoQ
Shares Held
388,682
-9.3% QoQ
Ownership
0.261%
of shares outstanding
% of Portfolio
3.66%
of 13F equity value
Holder Rank
#53
of 325 holders
Holding Since
Jun 2020
19 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PCVX Over Time
Shares Held
Position Value (USD)
Derivatives in PCVX
reported options exposure · as of Sep 30, 2025CallValue
$252,140
CallShares
7,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Ikarian Capital, LLC holds $559,861,982 across 103 Biotechnology names. PCVX ranks #5 (4.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
328,635 | $43,793,900 | |
| 2 | KOD |
Kodiak Sciences Inc.
|
1,059,730 | $41,287,080 | |
| 3 | ALMS |
Alumis Inc.
|
870,548 | $24,497,220 | |
| 4 | PRAX |
Praxis Precision Medicines, Inc.
|
72,842 | $24,386,773 | |
| 5 | PCVX |
Vaxcyte, Inc.
This page
|
388,682 | $22,594,084 | |
| 6 | CLDX |
Celldex Therapeutics, Inc.
|
478,500 | $17,804,985 | |
| 7 | RCUS |
Arcus Biosciences, Inc.
|
504,559 | $15,555,553 | |
| 8 | RLMD |
Relmada Therapeutics, Inc.
|
2,148,359 | $14,866,644 |
All Filings in PCVX
Export CSV
21 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $22,594,084 | 388,682 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $24,910,711 | 428,682 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $17,472,387 | 378,682 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $252,140 | 7,000 | Call | Sole | 2025-11-14 | |
| 2025-09-30 | $11,226,785 | 311,682 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $224,319 | 6,900 | Call | Sole | 2025-08-14 | |
| 2025-06-30 | $9,915,550 | 305,000 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $7,552,000 | 200,000 | Shares | Sole | 2025-05-15 | |
| 2023-09-30 | $7,260,418 | 142,417 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $6,991,600 | 140,000 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $8,433,000 | 225,000 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $11,987,500 | 250,000 | Shares | Sole | 2023-02-14 | |
| 2022-06-30 | $4,917,564 | 225,991 | Shares | Sole | 2022-08-12 | |
| 2022-03-31 | $7,631,182 | 315,991 | Shares | Sole | 2022-05-13 | |
| 2021-12-31 | $7,020,690 | 295,111 | Shares | Sole | 2022-02-14 | |
| 2021-09-30 | $7,486,966 | 295,111 | Shares | Sole | 2021-11-15 | |
| 2021-06-30 | $10,086,956 | 448,110 | Shares | Sole | 2021-08-18 | |
| 2021-03-31 | $9,896,922 | 501,110 | Shares | Sole | 2021-08-18 | |
| 2020-12-31 | $7,336,242 | 276,110 | Shares | Sole | 2021-02-12 | |
| 2020-09-30 | $795,511 | 16,110 | Shares | Sole | 2020-11-16 | |
| 2020-06-30 | $4,419,488 | 139,813 | Shares | Sole | 2020-08-14 | |
| No filing history on record for this holder in this stock. | ||||||